查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
放射組學市場——全球行業規模、份額、趨勢、競爭、機遇和預測：按形態、圖像類型、技術、應用、地區和競爭對手分類（2018-2028 年）
市場調查報告書
商品編碼
1244135

放射組學市場——全球行業規模、份額、趨勢、競爭、機遇和預測：按形態、圖像類型、技術、應用、地區和競爭對手分類（2018-2028 年）

Radiomics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Modality, By Image Type, By Technology, By Application, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 118 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在 2018-2028 年的預測期內，全球放射組學市場預計將以驚人的速度增長。

這可能是由於癌症等各種慢性病的患病率越來越高，需要準確的診斷和治療。 根據世界癌症觀察站的數據，2020 年報告的新癌症病例總數約為 19,292,789 例。 其中，2020 年將報告 10,065,305 例男性癌症新病例和 9,227,484 例女性癌症新病例。 對改進疾病診斷、預後和臨床決策支持的需求不斷增長，預計將為全球放射組學市場的增長帶來新的前景。

醫療行業數字化和人工智能應用的推進

在過去的幾十年裡，醫學領域已穩步將常規臨床程序中生成的信息數字化。 隨著醫療記錄變得更加數字化，用於分析它們的軟件也在不斷發展並變得更加複雜。 與此同時，人工智能（AI）的研究也取得了進展，其技術和軟件工具已經跳出了計算機科學系，現在被應用到各個領域。 因此，醫療保健行業近年來人工智能應用程序的使用顯著增加。 這些應用程序旨在支持臨床決策並簡化醫生每天必須執行的重複性任務。

放射組學在現代數學分析的幫助下增強了醫生可用的數據。 從根本上說，放射組學的概念在腫瘤學領域最為普遍，它基於這樣一種假設，即某些特定疾病的信息存在於人眼無法察覺的生物醫學圖像中。

在醫學圖像的放射組學分析中，利用從正電子 CT、MRI 和 PET 獲得的圖像信息的附加值，跨模態進行綜合分析，而不是單獨評估每個模態。多種模態可用，因為有可能 因此，人工智能與醫療保健行業的整合將在未來推動全球放射組學市場的發展。

在醫學診斷中越來越依賴放射學

醫學診斷成像不僅有助於成人的診斷，也有助於兒童的診斷，並開闢了新的治療方法。

根據國家衛生服務局 (NHS) 的一份報告，2018 年 10 月至 2019 年 9 月期間，英格蘭進行了大約 4520 萬次影像學檢查。 其中，2019 年 9 月僅進行了 358 萬次影像學研究。

這種升級可歸因於醫生和患者需求的增加、技術的改進以及人口經濟狀況的改善。 計算機斷層掃描和 CT 掃描在過去十年中增長了約 8%。 一項研究發現，從 2001 年到 2010 年，因呼吸系統疾病而進行急診科 CT 掃描的比率增加了四倍。

技術進步導致越來越多的醫生要求進行 CT 掃描和 MRI 檢查，以了解可以通過更簡單的影像學檢查的情況。 與普通 X 光片相比，CT 掃描可以更好地了解病情。 例如，用於確認和隨訪肺栓塞的首選成像技術是 CT 肺動脈造影。 主要原因是它的高速和高分辨率。 由於 CT 掃描具有高度敏感性、特異性和高度可見性，因此它們可以檢測到胸部 X 光檢查可能會漏掉的小空腔。 它還可以檢測胸部 X 光檢查可能漏掉的小病灶。 此外，一些區域，如肺底部和肺舌，可以更好地觀察。 因此，在醫學診斷中越來越依賴放射學為全球放射組學市場提供了有利可圖的增長機會。

老年人口增長及相關疾病

隨著年齡的增長，我們患疾病的風險也會增加。 根據美國疾病控制和預防中心 (CDC) 的數據，大約 80% 的美國老年人至少患有一種慢性病。 此外，美國醫學協會 (AMA) 估計，到 2030 年，大約 60% 的 65 歲及以上的人將患有多種慢性病。 因此，世界上日益老齡化的人口將增加對更好的醫療保健設施、現代療法和藥物的需求。

此外，由於世界慢性病的增加，對最新診斷和治療方法的需求也在增加。 放射學技術和醫學成像，例如磁共振成像 (MRI)、計算機斷層掃描 (CT)、超聲和血管造影，主要用於多種癌症的臨床治療。 此外，由於不健康生活方式的增加和人口老齡化，一些國家的癌症發病率正在飆升，增加了對放射組學等新技術的接受度。 因此，老年人口的增加和癌症患者數量的增加將推動全球放射組學市場。

市場細分

全球放射組學市場可以根據模式、成像類型、技術、應用、地區和公司進行細分。 基於模式，市場分為磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等。 根據圖像類型，市場分為 2D 和 3D。 基於技術，市場分為工程特徵和深度學習。 根據應用，市場分為核醫學、醫學影像、精準醫學、腫瘤學等。

公司簡介

全球放射組學市場的主要參與者包括 Radiomics.io（計算成像和生物信息學實驗室）、Radiomics Bio（比利時）、Health Innovation Ventures (HIV)、Sophia Genetics SA、HealthMyne Inc、Oncoradiomics 和 ptTheragnostic BV，以及其他的。

報告範圍

本報告將全球放射組學市場分為以下幾類，以及下面詳述的行業趨勢：

按模式劃分的放射組學市場

  • 磁共振成像 (MRI)
  • 計算機斷層掃描 (CT)
  • PET（正電子發射斷層掃描）
  • 其他

放射組學市場，按圖像類型：

  • 二維
  • 3D

放射組學市場，按技術

  • 工程功能
  • 深度學習

放射組學市場，按應用

  • 核醫學
  • 醫學成像
  • 精準醫學
  • 腫瘤學
  • 其他

按地區劃分的放射組學市場

  • 北美
    • 美國
    • 墨西哥
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 阿聯酋
    • 科威特

競爭格局

公司簡介：對全球放射組學市場主要參與者的深入分析。

可自定義：

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第 4 章 VOC（客戶之聲）

  • 品牌知名度
  • 放射組學對各種治療領域的影響
  • 引入放射組學的障礙

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分：按開發階段
  • 管道細分：按狀態
  • 渠道細分：按研究應用
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第六章專利分析

第7章全球放射組學市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按模式（磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等）
    • 按圖片類型（2D/3D）
    • 按技術（工程化功能與深度學習）
    • 按應用（核醫學、醫學成像、精準醫學、腫瘤學等）
    • 按地區
    • 按公司分類（2022 年）
  • 產品市場地圖
    • 按方式
    • 按圖片類型
    • 按技術
    • 通過申請
    • 按地區

第八章北美放射組學市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按模式（磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等）
    • 按圖片類型（2D/3D）
    • 按技術（工程化功能與深度學習）
    • 按應用（核醫學、醫學成像、精準醫學、腫瘤學等）
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：歐洲放射組學市場的前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按模式（磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等）
    • 按圖片類型（2D/3D）
    • 按技術（工程化功能與深度學習）
    • 按應用（核醫學、醫學成像、精準醫學、腫瘤學等）
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第 10 章亞太放射組學市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按模式（磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等）
    • 按圖片類型（2D/3D）
    • 按技術（工程化功能與深度學習）
    • 按應用（核醫學、醫學成像、精準醫學、腫瘤學等）
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第11章南美放射組學市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按模式（磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等）
    • 按圖片類型（2D/3D）
    • 按技術（工程化功能與深度學習）
    • 按應用（核醫學、醫學成像、精準醫學、腫瘤學等）
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 12 章中東和非洲放射組學市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按模式（磁共振成像 (MRI)、計算機斷層掃描 (CT)、正電子發射斷層掃描 (PET) 等）
    • 按圖片類型（2D/3D）
    • 按技術（工程化功能與深度學習）
    • 按應用（核醫學、醫學成像、精準醫學、腫瘤學等）
    • 按國家
  • MEA：國家分析
    • 南非 Radiomix
    • 沙特阿拉伯放射組學
    • 阿聯酋 Radiomix
    • 科威特放射組學

第 13 章市場動態

  • 司機
    • 人工智能在醫學影像診斷中的融合
    • 提高輻射在醫學診斷中的可靠性
    • 患癌症和心血管疾病的人口增加
  • 做
    • 成像協議未標準化/技術限制
    • 關於醫院預算削減
    • 缺乏驗證和假陽性結果的風險

第十四章市場趨勢與發展

  • 不斷發展的研究和投資活動
  • 新興國家的商機
  • 致力於引入更好的醫療保健設施

第15章競爭格局

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（As Reported）
  • Recent Developments
  • SWOT Analysis
    • Radiomics.io（Computational Imaging & Bioinformatics Lab）
    • Radiomics Bio（Belgium）
    • Health Innovation Ventures（HIV）
    • Sophia Genetics SA
    • HealthMyne Inc
    • Oncoradiomics
    • ptTheragnostic BV

第16章 戰略建議

簡介目錄
Product Code: 7872

Global Radiomics Market is projected to grow at a formidable rate in the forecast period, 2018-2028. This can be attributed to the growing prevalence of various chronic diseases such as cancer which require accurate diagnosis and treatment. According to the global cancer observatory, the total number of new cancer cases reported in 2020 was around 19,292,789. Out of this, 10,065,305 new cancer cases were reported in males, and in females were around 9,227,484 in 2020. The rising need of improving disease diagnosis, prognosis, and clinical decision support is expected to create new prospects for the growth of global radiomics market.

Radiomics is a quantitative method of approaching medical imaging that seeks to improve the data already available to doctors through sophisticated mathematical analysis. Using analysis techniques from the field of artificial intelligence, radiomics evaluate textural information by mathematically extracting the spatial patterns of signal intensities and pixel interconnections. The potential of radiomics to improve clinical decision-making has been highlighted by numerous research from various imaging domains that have been published so far. The numerous technical parameters impacting the retrieved radiomic properties are the primary cause of the numerous significant hurdles the area is currently facing.

Increased Digitization and Use of Artificial Intelligence in the Healthcare Industry

The digitization of information, produced during normal clinical procedures has increased steadily in medicine over the past few decades, much like it has in many other spheres of human endeavor. As more medical records were made available in digital form, ever-evolving, and more complex software was created to analyze them. At the same time, research on artificial intelligence (AI) has long advanced to the point where its techniques and software tools are sophisticated enough to leave computer science departments and find use in an expanding number of fields. As a result, the medical industry has seen a significant rise in the use of AI applications in recent years. These apps are intended to help clinical decision-making and simplify the repetitive tasks that physicians must perform daily.

Radiomics enhances the available data to physicians with the help of modern mathematical analysis. The concept of radiomics has been most widely implied in the field of oncology basically on the assumption of the presence of certain disease-specific information not perceptible by the human eye in biomedical images.

Different modalities can aid in radiomics analysis on medical images, employing the potential additive value of imaging information retrieved from positron-emission-tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI), rather than assessing each modality on its own, thus permitting an integrated cross-modality approach. Therefore, the integration of AI into the healthcare industry will fuel the global radiomics market in the future.

Increased Dependency on Radiology for Medical Diagnosis

Medical Imaging procedures facilitate diagnosis and pave an approach for the treatment of adults as well as children and lately, there has been a remarkable rise in the use of these techniques.

Between October 2018 and September 2019, about 45.2 million imaging tests were carried out in England, according to a report by the National Health Service (NHS). Out of these, 3.58 million imaging tests were just conducted in September 2019.

This escalation can be attributed to increased demand by physicians and patients, technological improvements, and better financial conditions for people. Computed Tomography or CT scans have seen a rise of about 8% in the past ten years. It has been revealed by a survey that the rate of CT scans being conducted for respiratory diseases in the emergency department has increased by four folds between 2001 and 2010.

Technological advancements have led to more physicians calling for CT scans and MRIs even for conditions that could be investigated with simpler imaging techniques. An improved view of pathologies can be obtained from a CT scan than a plain radiograph. For example, the best imaging technique suitable for identification and follow-up on pulmonary embolism is CT pulmonary angiography. The chief reason for this is its fast speed and high resolution. CT scan has greater sensitivity and specificity along with enhanced visualization due to which it has the potential to identify small opacities that might have been skipped during chest X-rays. Also, it can offer improved views of some regions such as lung lingula and lung bases. This increased dependency on radiology for medical diagnosis is offering lucrative growth opportunities for the global radiomics market.

Growing Geriatric Population and Associated Diseases

With advancing age, the risk of contracting a disease also increases. Nearly 80% of elderly people in the United States have at least one chronic disease, according to the Centers for Disease Control and Prevention (CDC). Furthermore, it has been estimated by the American Medical Association (AMA) that about 60% of individuals with an age of 65 or above will be living with more than one chronic condition by the year 2030. Therefore, the rise in the geriatric population in the world will fuel the necessity for better healthcare facilities and modern treatment options as well as medications.

The increased incidences of chronic diseases worldwide will drive the demand for modern diagnostic and treatment options. Radiology techniques or medical imaging procedures such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scans, ultrasound, and angiography are principally deployed for clinical procedures carried out for several cancers. Also, with a rise in unhealthy lifestyle habits and a rising elderly population, the incidence of cancer is on a surge across several countries, thereby raising the acceptance of novel technologies like radiomics. Hence, the growing geriatric population along with rising cancer cases will propel the global radiomics market.

Market Segmentation

Global radiomics market can be segmented based on modality, image type, technology, application, region, and company. Based on modality, the market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron-emission tomography (PET), and others. Based on image type, the market is split into 2D and 3D. Based on technology, the market is divided into engineered features and deep learning. Based on application, the market is fragmented into nuclear medicine, medical imaging, precision medicine, oncology, and others.

Company Profiles

Some of the leading players operating in the global radiomics market are Radiomics.io (Computational Imaging & Bioinformatics Lab), Radiomics Bio (Belgium), Health Innovation Ventures (HIV), Sophia Genetics SA, HealthMyne Inc, Oncoradiomics, and ptTheragnostic BV, among others.

Report Scope:

In this report, global radiomics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiomics Market, By Modality:

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron-Emission-Tomography (PET)
  • Others

Radiomics Market, By Image Type:

  • 2D
  • 3D

Radiomics Market, By Technology:

  • Engineered Features
  • Deep Learning

Radiomics Market, By Application:

  • Nuclear Medicine
  • Medical Imaging
  • Precision Medicine
  • Oncology
  • Others

Radiomics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global radiomics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Brand Awareness
  • 4.2. Impact of Radiomics on Different Therapeutic Areas
  • 4.3. Barriers to Adoption of Radiomics

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patents Analysis

7. Global Radiomics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron-Emission-Tomography (PET), Others)
    • 7.2.2. By Image Type (2D v/s 3D)
    • 7.2.3. By Technology (Engineered Features v/s Deep Learning)
    • 7.2.4. By Application (Nuclear Medicine, Medical Imaging, Precision Medicine, Oncology, Others)
    • 7.2.5. By Region
    • 7.2.6. By Company (2022)
  • 7.3. Product Market Map
    • 7.3.1. By Modality
    • 7.3.2. By Image Type
    • 7.3.3. By Technology
    • 7.3.4. By Application
    • 7.3.5. By Region

8. North America Radiomics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron-Emission-Tomography (PET), Others)
    • 8.2.2. By Image Type (2D v/s 3D)
    • 8.2.3. By Technology (Engineered Features v/s Deep Learning)
    • 8.2.4. By Application (Nuclear Medicine, Medical Imaging, Precision Medicine, Oncology, Others)
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Radiomics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Modality
        • 8.3.1.2.2. By Image Type
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
    • 8.3.2. Mexico Radiomics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Modality
        • 8.3.2.2.2. By Image Type
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
    • 8.3.3. Canada Radiomics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Modality
        • 8.3.3.2.2. By Image Type
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application

9. Europe Radiomics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron-Emission-Tomography (PET), Others)
    • 9.2.2. By Image Type (2D v/s 3D)
    • 9.2.3. By Technology (Engineered Features v/s Deep Learning)
    • 9.2.4. By Application (Nuclear Medicine, Medical Imaging, Precision Medicine, Oncology, Others)
    • 9.2.5. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Radiomics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Modality
        • 9.3.1.2.2. By Image Type
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
    • 9.3.2. Germany Radiomics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Modality
        • 9.3.2.2.2. By Image Type
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
    • 9.3.3. United Kingdom Radiomics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Modality
        • 9.3.3.2.2. By Image Type
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
    • 9.3.4. Italy Radiomics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Modality
        • 9.3.4.2.2. By Image Type
        • 9.3.4.2.3. By Technology
        • 9.3.4.2.4. By Application
    • 9.3.5. Spain Radiomics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Modality
        • 9.3.5.2.2. By Image Type
        • 9.3.5.2.3. By Technology
        • 9.3.5.2.4. By Application

10. Asia-Pacific Radiomics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron-Emission-Tomography (PET), Others)
    • 10.2.2. By Image Type (2D v/s 3D)
    • 10.2.3. By Technology (Engineered Features v/s Deep Learning)
    • 10.2.4. By Application (Nuclear Medicine, Medical Imaging, Precision Medicine, Oncology, Others)
    • 10.2.5. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Radiomics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Modality
        • 10.3.1.2.2. By Image Type
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
    • 10.3.2. India Radiomics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Modality
        • 10.3.2.2.2. By Image Type
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
    • 10.3.3. Japan Radiomics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Modality
        • 10.3.3.2.2. By Image Type
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
    • 10.3.4. South Korea Radiomics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Modality
        • 10.3.4.2.2. By Image Type
        • 10.3.4.2.3. By Technology
        • 10.3.4.2.4. By Application
    • 10.3.5. Australia Radiomics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Modality
        • 10.3.5.2.2. By Image Type
        • 10.3.5.2.3. By Technology
        • 10.3.5.2.4. By Application

11. South America Radiomics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron-Emission-Tomography (PET), Others)
    • 11.2.2. By Image Type (2D v/s 3D)
    • 11.2.3. By Technology (Engineered Features v/s Deep Learning)
    • 11.2.4. By Application (Nuclear Medicine, Medical Imaging, Precision Medicine, Oncology, Others)
    • 11.2.5. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Radiomics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Modality
        • 11.3.1.2.2. By Image Type
        • 11.3.1.2.3. By Technology
        • 11.3.1.2.4. By Application
    • 11.3.2. Argentina Radiomics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Modality
        • 11.3.2.2.2. By Image Type
        • 11.3.2.2.3. By Technology
        • 11.3.2.2.4. By Application
    • 11.3.3. Colombia Radiomics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Modality
        • 11.3.3.2.2. By Image Type
        • 11.3.3.2.3. By Technology
        • 11.3.3.2.4. By Application

12. Middle East and Africa Radiomics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron-Emission-Tomography (PET), Others)
    • 12.2.2. By Image Type (2D v/s 3D)
    • 12.2.3. By Technology (Engineered Features v/s Deep Learning)
    • 12.2.4. By Application (Nuclear Medicine, Medical Imaging, Precision Medicine, Oncology, Others)
    • 12.2.5. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Radiomics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Modality
        • 12.3.1.2.2. By Image Type
        • 12.3.1.2.3. By Technology
        • 12.3.1.2.4. By Application
    • 12.3.2. Saudi Arabia Radiomics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Modality
        • 12.3.2.2.2. By Image Type
        • 12.3.2.2.3. By Technology
        • 12.3.2.2.4. By Application
    • 12.3.3. UAE Radiomics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Modality
        • 12.3.3.2.2. By Image Type
        • 12.3.3.2.3. By Technology
        • 12.3.3.2.4. By Application
    • 12.3.4. Kuwait Radiomics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Modality
        • 12.3.4.2.2. By Image Type
        • 12.3.4.2.3. By Technology
        • 12.3.4.2.4. By Application

13. Market Dynamics

  • 13.1. Drivers
    • 13.1.1. Integration of Artificial Intelligence in Medical Imaging
    • 13.1.2. Increased Reliance Radiology for Medical Diagnosis
    • 13.1.3. Growing Population with Cancer and Cardiovascular Disorders
  • 13.2. Challenges
    • 13.2.1. Imaging Protocols Not Standardized/Technological Restraints
    • 13.2.2. Budget Cuts of Hospitals
    • 13.2.3. Lack of Validation and Risk of False-Positive Results

14. Market Trends & Developments

  • 14.1. Growing Research and Investment Activities
  • 14.2. Opportunities in Emerging Countries
  • 14.3. Adoption of Better Healthcare Facilities

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As Reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Radiomics.io (Computational Imaging & Bioinformatics Lab)
    • 15.6.2. Radiomics Bio (Belgium)
    • 15.6.3. Health Innovation Ventures (HIV)
    • 15.6.4. Sophia Genetics SA
    • 15.6.5. HealthMyne Inc
    • 15.6.6. Oncoradiomics
    • 15.6.7. ptTheragnostic BV

16. Strategic Recommendations